Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
Abstract Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-020-00629-4 |